---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003193"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T21:20:06.523633+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Provectus Biopharma approves up to $10M convertible loan financing for drug development

## Summary
- Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.
- Loan bears 8% annual interest; principal and interest convertible into Series D-1 Preferred at $2.8620 per share, each convertible into 10 common shares.
- Proceeds to fund drug discovery and development program and general & administrative expenses.
- Company closed 2024 Financing with $1M in convertible promissory notes received as of January 15, 2025.
- Issuance of notes exempt from registration under Section 4(a)(2) or Rule 506 of Regulation D.

## SEC filing metadata
- accession: 0001493152-25-003193
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/0001493152-25-003193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003193
- JSON: https://secwatch.observer/filing/0001493152-25-003193.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.